^
Association details:
| Biomarker: | HDAC2 expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) + abexinostat (CG-781) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
Excerpt:
Peripheral blood histone acetylation and HDAC2 gene expression were associated with durable response to treatment….Upon treatment with the combination of pazopanib plus abexinostat, there was an immediate tumor response and the patient remains on study with ongoing partial response for > 3.5 years’ duration.
DOI:
10.1200/JCO.2016.70.5350
Trial ID:
